Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults

Inclusion Criteria: * HIV-1 and -2 uninfected * Good general health * Pre-existing adenovirus 5 (Ad5) neutralizing antibody titers of a 1:12 ratio or greater * Hepatitis B surface antigen negative * Anti-hepatitis C virus (anti-HCV) antibody negative or negative HCV PCR if anti-HCV antibody is positive * Have access to a participating HIV Vaccine Trials Unit (HVTU) and are willing to be followed during the study * Willing to receive HIV test results * Able to understand the vaccination procedure * Willing to use acceptable forms of contraception Exclusion Criteria: * HIV vaccines or placebos in prior HIV trial. Participants who can provide documentation that they received a placebo in a prior HIV trial may be eligible. * Immunosuppressive medications within 168 days prior to first study vaccination * Blood products within 120 days prior to first study vaccination * Immunoglobulin within 60 days prior to first study vaccination * Live attenuated vaccines within 30 days prior to first study vaccination * Investigational research agents within 30 days prior to first study vaccination * Medically indicated subunit or killed vaccines within 14 days prior to first study vaccination * Allergy treatment with antigen injections within 30 days prior to first study vaccination * Current anti-tuberculosis (TB) preventive therapy or treatment * Clinically significant medical condition, abnormal physical exam findings, abnormal laboratory results, or past medical history that may affect…